4.6 Article

Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis

期刊

MOLECULAR CARCINOGENESIS
卷 58, 期 1, 页码 42-54

出版社

WILEY
DOI: 10.1002/mc.22905

关键词

apoptosis; esophageal squamous cell carcinoma; NOXA; P5091; USP7

资金

  1. National Natural Science Foundation Grant of China [81001102, 81101894, 81672421, U1604189]
  2. Natural Science Foundation of Henan Province [162300410302]
  3. Outstanding Young Talent Research Fund of Zhengzhou University [51999223, 32210449]
  4. Program for Science & Technology Innovation Talents in Universities of Henan Province [18HASTIT046]

向作者/读者索取更多资源

Increasing evidence suggests that deubiquitinase USP7 participates in tumor progression by various mechanisms and serves as a potential therapeutic target. However, its expression and role in esophageal cancer remains elusive; the anti-cancer effect by targeting USP7 still needs to be investigated. Here, we reported that USP7 was overexpressed in esophageal squamous cell carcinoma (ESCC) tissues compared with adjacent tissues, implying that USP7 was an attractive anticancer target of ESCC. Pharmaceutical or genetic inactivation of USP7 inhibited esophageal cancer cells growth in vitro and in vivo and induced apoptosis. Mechanistically, inhibition of USP7 accumulated poly-ubiquitinated proteins, activated endoplasmic reticulum stress, and increased expression of ATF4, which transcriptionally upregulated expression of NOXA and induced NOXA-mediated apoptosis. These results provide an evidence for clinical investigation of USP7 inhibitors for the treatment of ESCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Essential amino acids deprivation is a potential strategy for breast cancer treatment

Yajie Zhao, Chunrui Pu, Zhenzhen Liu

Summary: This study found that the SLC7A5 to SLC7A8 Ratio (SSR) score is correlated with EAAs metabolism in breast cancer (BC), and high EAAs metabolism is associated with poor prognosis and immune suppression in BC.

BREAST (2022)

Article Oncology

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial

Liulu Zhang, Zhi-Yong Wu, Jie Li, Ying Lin, Zhenzhen Liu, Yin Cao, Gangling Zhang, Hong-Fei Gao, Mei Yang, Ci-Qiu Yang, Teng Zhu, Min-Yi Cheng, Fei Ji, Jieqing Li, Kun Wang

Summary: In a randomized controlled trial, it was found that the addition of carboplatin to neoadjuvant chemotherapy significantly improved the pathologic complete response rate in patients with untreated stage II-III TNBC compared to anthracycline-based regimens. Despite the different treatment protocols, overall survival and event-free survival rates were comparable between the two groups after a 37-month follow-up period.

INTERNATIONAL JOURNAL OF CANCER (2022)

Article Oncology

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen, Armando Orlandi, Naohiro Ishii, Kazuaki Takabe, Gianluca Franceschini, Francesco Ricci, Claire Verschraegen, Zhenzhen Liu, Mengwei Zhang, Huimin Lv, Liping Liu, Xiaohong Yang, Huawu Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Xiuchun Chen, Jianghua Qiao, Guifang Zhang

Summary: This study investigated the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases. The combination therapy showed a high intracranial objective response rate in patients who had not received radiotherapy and had acceptable safety profiles.

LANCET ONCOLOGY (2022)

Article Surgery

Pyroptosis-Related Signatures for Predicting Prognosis in Breast Cancer

Tong Ren, Xuhui Guo, Jingyang Zhang, Zhenzhen Liu

Summary: Female breast cancer (BC) is the most common cancer in the world, with higher mortality in transitioning countries. Pyroptosis, a form of inflammation-dependent programmed cell death, plays an important role in the progression of BC. This study used comprehensive bioinformatics analysis to investigate the expression of pyroptosis-related genes in BC and their relationship with tumor progression. Pyroptosis-related genes may serve as new prognostic biomarkers and therapeutic targets for BC.

FRONTIERS IN SURGERY (2022)

Article Oncology

A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer

Guangshi Du, Jian Sun, Zhen Li, Qian Zhang, Wenjing Liu, Chuanyu Yang, Ping Zhao, Xinye Wang, Qiyan Yin, Yao Luo, Jinhuan Song, Yi Wen, Haixia Wang, Chuan-Huizi Chen, Guosheng Hu, Zhongmei Zhou, Xiaoyun Mao, Wen Liu, Zhenzhen Liu, Dewei Jiang, Ceshi Chen

Summary: This study identifies the promoting role of KPRT4 in BLBC cell proliferation and reveals the underlying mechanism of mutual regulation between KLF5 and KPRT4. Additionally, the study finds that targeting KPRT4 can attenuate tumor growth, suggesting KPRT4 as a major molecule for BLBC progression.

CANCER LETTERS (2022)

Article Multidisciplinary Sciences

ELOVL2-AS1 inhibits migration of triple negative breast cancer

Mingda Zhu, Jingyang Zhang, Guangyu Li, Zhenzhen Liu

Summary: A key enhancer RNA region (ELOVL2-AS1) in breast cancer (BRCA) was identified through integrated analysis, which showed a direct regulatory interaction with ELOVL2 gene and lower expression in triple negative breast cancer (TNBC).
Article Oncology

Exploration of the breast ductal carcinoma in situ signature and its prognostic implications

Jiao Zhang, Hui Lin, Lei Hou, Hui Xiao, Xilong Gong, Xuhui Guo, Xuchen Cao, Zhenzhen Liu

Summary: This study identified differentially expressed genes in DCIS and normal tissue and validated a six-core gene signature with potential for prognostic prediction in DCIS.

CANCER MEDICINE (2023)

Article Oncology

Impact of Marital Status on Prognosis of Patients With Invasive Breast Cancer: A Population-Based Study Using SEER Database

Dechuang Jiao, Youzhao Ma, Jiujun Zhu, Hao Dai, Yue Yang, Yajie Zhao, Xuhui Guo, Zhenzhen Liu

Summary: This study found that marital status is an independent prognostic factor for invasive breast cancer patients. Married patients have better survival rates compared to unmarried patients. Additional psychosocial and emotional support may be necessary for unmarried patients aged 35 and above in order to achieve longer survival.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Efficacy and Safety of Mitoxantrone Hydrochloride Injection for Tracing Axillary Sentinel Nodes in Breast Cancer: A Self-Controlled Clinical Trial

Dechuang Jiao, Benlong Yang, Jiajian Chen, Chunjian Wang, Lidan Jin, Wenhe Zhao, Xueqiang Gao, Haibo Wang, Jun Li, Haidong Zhao, Di Wu, Zhimin Fan, Shujun Wang, Zhenzhen Liu, Yongsheng Wang, Jiong Wu

Summary: This study evaluated the efficacy and safety of Mitoxantrone hydrochloride injection for tracing (MHI) in sentinel lymph node biopsy (SLNB) for breast cancer. The results showed that MHI has comparable efficacy to radionuclides and can be used alone or in combination with radioactive substances for SLNB.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer

Xin Zhao, Liang Jin, Yujie Liu, Zhenzhen Liu, Qiang Liu

Summary: This study using bioinformatics analysis found that increased expression levels of SLC-related glutamine transporters were associated with poor prognosis in breast cancer patients, while decreased expression levels of SLC6A14 and SLC38A1 were also associated with poor prognosis. Additionally, these SLC-related proteins may regulate the polarization of tumor-associated macrophages.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Article Oncology

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen

Jiujun Zhu, Dechuang Jiao, Chengzheng Wang, Zhenduo Lu, Xiuchun Chen, Lianfang Li, Xianfu Sun, Li Qin, Xuhui Guo, Chongjian Zhang, Jianghua Qiao, Min Yan, Shude Cui, Zhenzhen Liu

Summary: According to this study, the TCH + Py regimen has a higher pCR rate compared to the TCH regimen in neoadjuvant therapy for HER2-positive breast cancer, and a comparable pCR rate with the TCHP regimen.

CANCERS (2022)

Article Surgery

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database

Junzhao Wu, Minhao Lv, Peng Yuan, Youzhao Ma, Peiqi Tian, Lianfang Li, Chengzheng Wang, Zhenduo Lu, Min Yan, Xiuchun Chen, Zhenzhen Liu

Summary: This study found that patients with T1a,bN0M0 triple-negative breast cancer had a good prognosis with or without adjuvant chemotherapy after local therapy. Higher histologic grade and larger tumor size were associated with poorer prognosis, while the effect of age was complex. The data did not support the use of adjuvant chemotherapy in these patients.

GLAND SURGERY (2022)

Article Genetics & Heredity

Application of single-cell RNA sequencing analysis of novel breast cancer phenotypes based on the activation of ferroptosis-related genes

Shuochuan Liu, Yajie Zhao, Jiao Zhang, Zhenzhen Liu

Summary: Ferroptosis plays an important role in breast cancer, but its exploration is limited. In this study, a model related to ferroptosis activation was established using machine learning and validated to have a good prognostic capacity in breast cancer patients, providing insights into clinical treatment and preventing potential drug resistance. Furthermore, analysis of the tumor microenvironment revealed differences between high- and low-risk groups, offering molecular insights into ferroptosis in breast cancer patients.

FUNCTIONAL & INTEGRATIVE GENOMICS (2023)

Article Oncology

Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy

Youzhao Ma, Mingda Zhu, Minhao Lv, Peng Yuan, Xiuchun Chen, Zhenzhen Liu

Summary: This study aimed to determine the changes in prognostic factors following neoadjuvant therapy for HER2-positive breast cancer and the impact of clinicopathological characteristics of residual disease on prognosis. The results showed significant changes in HER2, ER, PR, and Ki-67 after neoadjuvant therapy, but these changes did not affect disease-free survival. Postoperative N stage, postoperative ER status, Miller-Payne grade, and targeted therapy were identified as independent prognostic factors for HER2-positive breast cancer after neoadjuvant therapy.

CANCER MEDICINE (2023)

Article Oncology

HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer

Youzhao Ma, Dechuang Jiao, Jingyang Zhang, Minhao Lv, Xiuchun Chen, Zhenzhen Liu

Summary: This study investigated the clinicopathological and prognostic characteristics of HER2-low status in a large sample of early-stage triple-negative breast cancer datasets. The findings suggest that HER2-low breast cancer is associated with better breast cancer-specific survival, especially in high-risk groups.

ONCOLOGIST (2023)

暂无数据